Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Therapeutic resistance is a frequent problem of cancer treatment and a leading cause of mortality in patients with metastatic colorectal cancer (CRC). Recent insight into the mechanisms that confer multidrug resistance has elucidated that the ATP-binding cassette (ABC) superfamily G member 2 (ABCG2) assists cancer cells in escaping therapeutic stress caused by toxic chemotherapy. Therefore, it is necessary to develop ABCG2 inhibitors.
Objectives: In the present study, we investigated the inhibitory effect of KU55933 on ABCG2 in CRC.
Methods: The cytotoxicity assay and drug accumulation assay were used to examine the inhibitory effect of KU55933 on ABCG2. The protein expressions were detected by Western blot assay. The docking assay was performed to predict the binding site and intermolecular interactions between KU55933 and ABCG2.
Results: KU55933 was more potent than the known ABCG2 inhibitor fumitremorgin C to enhance the sensitivity of mitoxantrone and doxorubicin and the intracellular accumulation of mitoxantrone, doxorubicin and rhodamine 123 inside CRC cells with ABCG2 overexpression. Moreover, KU55933 did not affect the protein level of ABCG2. Furthermore, the docking data showed that KU55933 was tightly located in the drug-binding pocket of ABCG2.
Conclusion: In summary, our data presented that KU55933 could effectively inhibit the drug pump activity of ABCG2 in colorectal cancer, which is further supported by the predicted model that showed the hydrophobic interactions of KU55933 within the drug-binding pocket of ABCG2. KU55933 can potently inhibit the activity of ABCG2 in CRC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1574892817666220112100036 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rutin Alleviates Breast Cancer Resistance to Tamoxifen By Downregulating ABC Transporters, Inducing ROS Generation and Resetting Redox Status.
J Biochem Mol Toxicol
September 2025
Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.
Breast cancer is one of the most lethal cancers in women worldwide. Tamoxifen (TAM), a nonsteroidal antiestrogen, is a highly successful treatment for breast cancer. However, developed resistance to TAM can substantially impair chemotherapy efficacy, resulting in poor prognosis and cancer recurrence.
View Article and Find Full Text PDFProgress in animal models for studying hyperuricemia.
Front Pharmacol
August 2025
The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, China.
Hyperuricemia (HUA) is a prevalent metabolic disorder driven by dysregulated purine metabolism and impaired urate excretion, and robust animal models are critical for elucidating its pathophysiology and guiding therapy development. This review systematically examines chemically induced, gene-edited, environmental, exercise and microbiota-based HUA models across rodents, poultry, primates, zebrafish and silkworms, highlighting each model's strengths and limitations in mimicking human uric acid handling. We discuss how these models have validated standard urate-lowering treatments-such as xanthine oxidase inhibitors and uricosurics-and uncovered emerging therapeutic targets, including the gut-NLRP3 inflammasome axis and SIRT1-mediated ABCG2 regulation.
View Article and Find Full Text PDFFucoidan-driven Bacteroides xylanisolvens HS-1 alleviates hyperuricemia by promoting intestinal uric acid excretion via the PPARγ/ABCG2 signaling pathway.
Int J Biol Macromol
September 2025
Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266001, PR China. Electronic address:
The rising prevalence of hyperuricemia and associated complications present a substantial global health challenge. Fucoidan, a natural sulfate-rich polysaccharide degraded by gut microbiota, is under investigation as a potential therapeutic agent for reducing uric acid levels. However, the precise mechanism underlying its effects remains unclear.
View Article and Find Full Text PDFLoss of CD90 alters EMT-associated features and drug sensitivity in U-CH1 chordoma cells.
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Department of Medical Genetics, School of Medicine, Yeditepe University, Istanbul, 34755, Turkey.
Chordoma is a rare, slow-growing malignancy of notochordal origin characterized by a high degree of chemoresistance and limited therapeutic responsiveness. Despite advances in molecular profiling, the mechanisms underlying its cellular plasticity and therapy evasion remain incompletely defined. Emerging evidence across solid tumors suggests that cancer stem-like cells (CSCs) and the epithelial-to-mesenchymal transition (EMT) play central roles in driving tumor progression, metastatic potential, and drug resistance.
View Article and Find Full Text PDFNew players from the old chalcone scaffold: Synthesis, identification, and characterization of new potent ABCG2 inhibitors.
Eur J Med Chem
December 2025
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, 80210-170, PR, Brazil; Graduate Program in Cell and Molecular Biology, Federal University of Parana, Curitiba, PR, Brazil. Electronic address:
The ABCG2 transporter is an efflux pump that can transport various anticancer drugs and is strongly associated with multidrug resistance (MDR) in cancer. A promising strategy to combat MDR mediated by this transporter is through functional inhibition. However, there are currently no potent selective ABCG2 inhibitors in clinical trials.
View Article and Find Full Text PDF